Oncology Research and Treatment最新文献

{"title":"Onkopedia: What's New? Systemic Tumor Treatment in Pregnancy.","authors":"Georg Maschmeyer, Tanja Fehm, Sibylle Loibl, Ralf Dittrich, Inken Hilgendorf","doi":"10.1159/000547137","DOIUrl":"10.1159/000547137","url":null,"abstract":"<p><strong>Background: </strong>An evidence-based clinical practice guideline for systemic cancer treatment in pregnant women is lacking.</p><p><strong>Summary: </strong>The German, Austrian, and Swiss Societies for Hematology and Medical Oncology have provided an updated guideline on systemic cancer treatment in pregnancy.</p><p><strong>Key messages: </strong>The gestational age and a multidisciplinary team are essential for treatment planning. A risk-benefit analysis is mandatory. Ultrasound and magnetic resonance imaging are preferred for diagnostic imaging during pregnancy. In the first trimester, there is an increased risk of malformations and miscarriages following systemic tumor therapy; therefore, such therapy is generally discouraged during this period. Systemic tumor therapy in the second and third trimester can result in outcomes comparable to a normal course of pregnancy and development. In cases of premature delivery, potential risks for the newborn should be considered. Systemically administered tumor therapeutics are dosed according to current standards. The use of certain medications, such as tyrosine kinase inhibitors, VEGF antibodies, anti-hormonal substances, and immune checkpoint inhibitors, is generally advised against during pregnancy. Supportive therapy agents can predominantly be used in the second and third trimesters without significant late effects for the newborn. The goal is a spontaneous delivery as for non-cancer patients; early induction of labor and Caesarian section (except for patients with cervical cancer) are discouraged. A minimum interval of 3 weeks between myelosuppressive systemic therapy and delivery is recommended to reduce potential complications. As a rule, normal early and late child development can be expected if established treatment recommendations are followed. Patient data should be entered into established registries.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"134-149"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144554068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis and Therapy of Ovarian Cancer, Part 3: Follow-Up Care, Recurrence, and Screening, the Full Round Circle.","authors":"Alaa El Housheimi, Sara Tato Varela, Walther Christian Kuhn","doi":"10.1159/000547282","DOIUrl":"10.1159/000547282","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OC) accounts for the most cancer deaths in women worldwide, despite it being the 8th most common one. Almost two-thirds or OC cases present in advanced stages (III/IV) and will require maintenance therapy lasting for up to 36 months in some patients. Despite the introduction of innovative treatments, OC recurs in about 80% of cases in advanced stage disease. Management of recurrent OC is based on multiple factors and includes either surgery, in suitable candidates, followed by chemotherapy or systemic treatment alone. Due to its heavy physical, psychological and economic burden, reducing mortality of OC through prevention and early diagnosis is of utmost importance.</p><p><strong>Summary: </strong>Prolonged maintenance treatment period in advanced OC led to a more complex follow-up care, which will start during active treatment and hence include management of therapy side effects. Intensifying follow-up through routine measurements of serum CA-125 and the consequent early induction of treatment in asymptomatic relapsed patients failed to improve overall survival compared to symptom oriented follow-up. In recurrent OC patients with a long treatment-free interval, good performance status, low ascitic fluid volume and completely operable tumor in the first diagnosis were found to benefit form a secondary cytoreductive surgery. Several drug classes were heavily tested in recurrent OC, antibody-drug conjugates (ADCs) have been showing some promising results in platinum-resistant recurrent OC. Studies investigating Immunotherapy on the other hand have been much less encouraging. Despite achieving a stage shift toward early stage detection in some trials, large, well-designed studies have so far failed to develop an effective OC screening program that reduces mortality.</p><p><strong>Key messages: </strong>Managing long-term treatment side effects has become an indispensable part of follow-up care in OC. Symptom oriented follow-up with tumor marker measurement and imaging reserved for symptomatic patients is the standard of care. Allocating the right therapy plan in patients with recurrent OC, to secondary cytoreductive surgery versus systemic treatment will significantly impact progression-free (PFS) and OS. To date, there is no effective screening program for prevention and early detection of OC.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"150-164"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structured Magnetic Resonance Imaging Assessment Improves Diagnosis of Pathological Complete Response in Rectal Cancer after Neoadjuvant Chemoradiation.","authors":"Moying Li, Tobias Dieckmann, Florian Herrle, Ralf-Dieter Hofheinz, Thomas Hielscher, Alexander Hertel, Sophia Schweitzer, Svetlana Hetjens, Johannes Betge, Sebastian Belle, Nadine Schulte, Christoph Reißfelder, Judit Boda-Heggemann, Constantin Dreher, Christoph Brochhausen, Matthias P Ebert, Matthias F Froelich, Tianzuo Zhan","doi":"10.1159/000548042","DOIUrl":"10.1159/000548042","url":null,"abstract":"<p><strong>Introduction: </strong>Precise prediction of pathological complete response (pCR) following neoadjuvant chemoradiotherapy (nCRT) in rectal cancer may identify candidates for non-operative management. The optimal selection of diagnostic tools is, therefore, of major clinical importance.</p><p><strong>Methods: </strong>Clinical, laboratory, endoscopic, and radiological data of patients with rectal cancer treated with nCRT and surgery at an academic medical center from 2010 to 2020 were retrospectively collected. Pre- and post-nCRT magnetic resonance imaging (MRI) was reviewed with a structured report template and assessed by magnetic resonance imaging tumor regression grade (mrTRG). Two senior radiologists reviewed mrTRG independently to determine the inter-reader agreement. Univariate logistic regression was applied to identify parameters that predict pCR. A multivariate prediction model was developed using L1-penalized logistic regression, with performance assessed by area under the curve (AUC) in the total cohort (apparent AUC) and by cross-validation (CV-AUC).</p><p><strong>Results: </strong>A total of 261 patients were identified, of whom 36 achieved pCR. Univariate analysis showed a significant correlation between post-nCRT features with pCR, including radiological T-stage (odds ratio [OR] 0.05 [0.02-0.15], p < 0.001), mrTRG (OR 0.13 [0.05-0.31], p < 0.001), and endoscopic response (OR 0.17 [0.05-0.54], p = 0.032). Of those, mrTRG showed the highest AUC of 0.77 with a substantial inter-reader agreement (kappa = 0.71, 95% confidence interval: 0.61-0.81). The multivariate predictive model selected eight pre- and post-nCRT parameters with an apparent AUC of 0.84 and a CV-AUC of 0.73.</p><p><strong>Conclusion: </strong>Therapy response assessed by MRI, particularly by mrTRG, strongly predicted pCR. Therefore, mrTRG should be implemented in routine assessment of rectal cancer treated by nCRT.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"179-191"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Is New in the German S3 Guideline on Gastric Cancer: Diagnosis, Staging, and Treatment.","authors":"Markus Moehler, Yvonne Huber, Jan Bornschein, Ines Gockel, Lars Grenacher, Peter Grimminger, Stefan Höcht, Christian Jenssen, Michael Klein, Sylvie Lorenzen, Helmut Messmann, Katja Ott, Christoph Röcken, Peter Thuß-Patience, Marino Venerito, Ulrich Wedding, Susanne Unverzagt","doi":"10.1159/000550791","DOIUrl":"10.1159/000550791","url":null,"abstract":"<p><strong>Background: </strong>Carcinomas of the stomach and esophagogastric junction (EGJ) are the fifth leading cause of cancer-related deaths worldwide. In Germany, gastric cancer ranks tenth in incidence across both sexes. The new German national guideline aims to provide the most relevant evidence-based recommendations on diagnosis and treatment of gastric and EGJ adenocarcinomas and has been comprehensively updated by an interdisciplinary panel of experts from national medical societies.</p><p><strong>Summary: </strong>The updated S3 guideline reflects the latest advances in diagnostics, improved palliative therapies, and supportive care. The objectives are to improve the quality of individual and broad care and to ensure consistent, evidence-based treatment strategies.</p><p><strong>Key messages: </strong>New recommendations introduce preventive strategies, including management of familial risk due to microsatellite instability (MSI) and H. pylori eradication. The biomarkers HER2, PD-L1, MSI, and Claudin 18.2 enable the use of targeted therapies that improve long-term outcomes in advanced disease. Combinations of chemotherapy with immunotherapy nivolumab, pembrolizumab, or tislelizumab significantly prolong survival compared with chemotherapy alone (e.g., nivolumab 14.4 vs. 11.1 months, HR 0.71; pembrolizumab 13.0 vs. 11.4 months, HR 0.75; tislelizumab 17.2 vs. 12.6 months, HR 0.74) with 5-year survival rates up to 16%. In patients with high Claudin 18.2 expression, zolbetuximab plus chemotherapy improved median survival to 16.4 vs. 13.4 months (HR 0.77). For patients in good general condition, subsequent lines of therapy including biomarker-driven approaches (trastuzumab deruxtecan, pembrolizumab) or third-line therapies (e.g., trifluridine tipiracil) and advanced molecular diagnostics are recommended after treatment failure.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"314-321"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the Proportion of Transplant-Eligible Patients in Diffuse Large B-Cell Lymphoma: Insights from German Hospital Billing Data.","authors":"Ann-Cathrine Froitzheim, Melina Sophie Kurte, Tabea Poos, Udo Holtick, Florian Kron","doi":"10.1159/ort/aecag003","DOIUrl":"10.1159/ort/aecag003","url":null,"abstract":"<p><p><p>Introduction: Treatment, according to guidelines, for second-line and beyond (2L+) therapy of diffuse large B-cell lymphoma (DLBCL) differentiates between transplant-eligible and transplant-ineligible patients. Transplant-eligible patients typically receive salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT) or chimeric antigen receptor T-cell therapy. Although literature suggests a 50-50 distribution between transplant-eligible and transplant-ineligible patients, real-world evidence from Germany is lacking. This study aimed to estimate the proportion of transplant-eligible and transplant-ineligible patients using intended-for-HD-ASCT national inpatient billing data to evaluate the validity of the commonly assumed distribution.</p><p><strong>Methods: </strong>Inpatient billing data from all German hospitals in 2024, provided by the Institute for the Hospital Remuneration System (InEK), were analyzed. Cases with the main diagnosis \"C83.3\" (DLBCL) defined the base population. Applying guideline-based first-line cure rates (60% [minimum]-70% [maximum]), the 2L population size was estimated. Transplant-eligible cases were identified via operation and procedure score codes for salvage immunochemotherapies (R-ICE, R-DHAP, R-GDP). The transplant-eligible proportion was calculated by dividing the number of transplant-eligible cases by the estimated 2L population. Sensitivity analyses were performed using data from 2022 to 2023, validating the 2L relapse/refractoriness rate assumption against German real-world claims data, and assessing potential impact of polatuzumab vedotin-related coding bias.</p><p><strong>Results: </strong>The base population included 32,851 DLBCL cases. Based on cure rate assumptions, the estimated 2L population size ranged from 9,855 (minimum) to 13,140 (maximum). A total of 7,523 cases were identified to have received salvage immunochemotherapy based on coding criteria. This corresponds to a transplant-eligible proportion of patients intended for HD-ASCT of 57% (minimum) and 76% (maximum). Sensitivity analyses yielded a transplant-eligible proportion range of 40-54% (2022) and 52-69% (2023), 52% when applying the relapse/refractoriness rate from German real-world claims data, and 34-46% when excluding polatuzumab vedotin-related cases.</p><p><strong>Conclusion: </strong>This analysis introduces a method for approximating the distribution of transplant eligibility among DLBCL patients intended for HD-ASCT in the 2L setting using real-world inpatient billing data. The results question the widely assumed balance between transplant-eligible and transplant-ineligible groups, indicating a possible tendency toward a slightly higher proportion of transplant-eligible cases which may be clinically eligible for HD-ASCT.</p>.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"423-431"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experiences in the Treatment of Immune Thrombocytopenia over a 2-Year Period.","authors":"Geothy Chakupurakal, Karl Verpoort, Florian Kaiser, Johannes Mohm, Stefan Feiten","doi":"10.1159/000553069","DOIUrl":"10.1159/000553069","url":null,"abstract":"<p><strong>Introduction: </strong>Immune thrombocytopenia (ITP) is an autoimmune disorder mostly treated in the outpatient setting. This study was conducted to analyze the real-world outcomes of outpatient care for ITP patients receiving treatment.</p><p><strong>Methods: </strong>Data from patients who had a diagnosis of primary ITP and on or requiring treatment between January, 2020 and December, 2021 in the routine outpatient practice were retrospectively analyzed.</p><p><strong>Results: </strong>Of 91 patients identified, at initial diagnosis, the mean age was 55 (range: 11-90). Eighty-one patients (89%) had a chronic ITP. The mean platelet count at the time of diagnosis was 26 g/L (range: 1-89 g/L). The primary indication for treatment was thrombocytopenia (n = 80, 88%); mean: 26.2 × 109/L (range: 1-89 × 109/L). The first-line treatment was mainly corticosteroids (56%, n = 51). The mean number of therapies and therapy lines was 3.45 (median: 2, range: 1-15) and 2.88 (median: 2, range: 1-10) respectively. Across all therapy lines, 82% of patients (n = 75) had corticosteroids, 77% (n = 70) thrombopoietin receptor agonists, 48% (n = 44) IVIG, 12% (n = 11) rituximab, 5% (n = 5) fostamatinib, and 6% (n = 7) splenectomy. A total of 314 therapies were administered during the study duration and patients achieved CR, R, and NR in 39% (123/314), 18% (56/314), and 43% (135/314), respectively. No grade III bleeding was documented during treatment.</p><p><strong>Conclusion: </strong>We conclude that ITP can be safely managed in the outpatient setting despite the challenges involved in the care of this patient cohort. Close cooperation with regional hospitals allows inpatient care when necessary.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"370-376"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148278298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis.","authors":"Sait Kitapli, Özgür Tanrıverdi, İsmail Bayrakci, Taliha Guclu, Bilgin Demir, Gokhan Colak, Ali Alkan, Merve Turan, Esin Oktay, Gamze Gokoz Dogu, Sernaz Uzunoglu, Sabri Barutca","doi":"10.1159/000550484","DOIUrl":"10.1159/000550484","url":null,"abstract":"<p><strong>Introduction: </strong>HER2-low breast cancer is a newly characterized subgroup with unclear prognostic implications. This study investigates the prognostic role of Ki67 in hormone receptor-positive (HR+) HER2-low and HER2-positive breast cancer.</p><p><strong>Methods: </strong>We retrospectively analyzed 224 HR+ breast cancer patients from four tertiary centers (96 HER2-low, 128 HER2-positive). Patients were stratified into stages 1-3 (n = 156) and stage 4 (n = 68). Survival outcomes were assessed according to HER2 and Ki67 status using Kaplan-Meier analysis and Cox regression.</p><p><strong>Results: </strong>HER2-low patients were older (≥65 years: 65% vs. 28%, p < 0.001). In stage 1-3 patients, disease-free survival (DFS) was significantly longer in the HER2-low subgroup (median: 86 vs. 59 months; p < 0.001) and in those with Ki67 < 20% (median: 74 vs. 34 months; p < 0.001). Multivariable analysis confirmed high Ki67 (HR: 1.664; 95% CI: 1.564-2.048; p < 0.001), hormone receptor negativity (HR: 1.967; 95% CI: 1.614-2.433; p = 0.020), larger tumor size, and axillary nodal involvement as independent predictors of poor DFS. Among stage 4 patients, overall survival (OS) did not differ significantly by HER2 status (34 vs. 28 months; p = 0.427) but was significantly shorter in those with Ki67 ≥ 20% (18 vs. 29 months; p < 0.001). In multivariable analysis, high Ki67 (HR: 2.174; 95% CI: 1.994-2.256; p < 0.001), hormone receptor negativity (HR: 1.649; 95% CI: 1.184-2.143; p < 0.001), and presence of brain metastasis (HR: 1.564; 95% CI: 1.379-1.994; p < 0.001) were independent predictors of poor OS.</p><p><strong>Conclusion: </strong>Ki67 appears to be an important prognostic biomarker in HR+ breast cancer across both HER2-low and HER2-positive subgroups. Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"246-261"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apatinib Mesylate in the Treatment of Advanced Triple-Negative Breast Cancer.","authors":"Xijia Huang, Chao Chen, Hao Zeng, Lili Wang, Mulan Chen, Jian Liu, Fan Wu, Weiwei Huang","doi":"10.1159/000551064","DOIUrl":"10.1159/000551064","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of conventional chemotherapy in treating metastatic triple-negative breast cancer (TNBC) is unsatisfactory. Apatinib, a small-molecule tyrosine kinase vascular inhibitor, is a multi-targeted antitumor angiogenesis agent that promotes apoptosis to inhibit tumors.</p><p><strong>Summary: </strong>Apatinib, when combined with chemotherapy, has demonstrated efficacy in treating advanced TNBC. Additionally, immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for metastatic TNBC; however, their efficacy still requires further improvement. One potential strategy to enhance the efficacy of ICIs in metastatic TNBC is through their combination with chemotherapy and anti-angiogenic agents. The combination of apatinib, chemotherapy, and ICIs has demonstrated favorable efficacy, with improved progression-free survival compared with the conventional chemotherapy for advanced TNBC. This warrants further exploration of its clinical value. This triple therapy exhibits synergistic effects rather than representing a simple combination of agents. Apatinib can reverse chemoresistance and enhance the efficacy of programmed death receptor-1 (PD-1) inhibitor therapy. Combining chemotherapeutic agents with ICIs is complementary, and apatinib, combined with chemotherapy, can modify the tumor microenvironment to improve the effectiveness of ICIs.</p><p><strong>Key messages: </strong>This review examines the role of apatinib in treating TNBC and explores its potential mechanisms when combined with chemotherapeutic agents and ICIs for advanced TNBC in the era of immunotherapy.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"288-297"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie: Wien, Österreich, 9. bis 12. Oktober 2026: ABSTRACTS.","authors":"","doi":"10.1159/ort/aecag001","DOIUrl":"https://doi.org/10.1159/ort/aecag001","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"49 Suppl. 2","pages":"1-356"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Introduction of Hypomethylation Agents and Venetoclax into Standard Care for Older Patients with Acute Myeloid Leukemia: A Retrospective Real-World Analysis of Feasibility, Safety, and Effectiveness from an Outpatient Hematology Center.","authors":"H Tilman Steinmetz, Jan Phillip Weber","doi":"10.1159/ort/aecag004","DOIUrl":"10.1159/ort/aecag004","url":null,"abstract":"<p><strong>Introduction: </strong>The combination of venetoclax (VEN) and a hypomethylation agent (HMA) was introduced for the treatment of acute myeloid leukemia (AML) because it achieved significantly better results compared to HMA monotherapy (HMA-mono). Since introducing a new method into standard care is always a challenge, the goal of this retrospective analysis was to examine AML treatment before and after the approval of HMA-VEN at an office-based center for hematology and oncology (MVZ).</p><p><strong>Methods: </strong>All newly diagnosed AML patients between January 2017 and April 2025 were fully documented and analyzed in an Excel database.</p><p><strong>Results: </strong>In total, 65 patients were included; of these, 22 (mean age 59.6 years (y) (SD 15.35)), were admitted to the university hospital. Of the remaining 43 patients (mean age 79.4 y (SD 5.86)), 1 was treated with cytosine arabinoside (ARA-C), 7 with best supportive care (BSC), 15 with HMA-mono, and 20 with the HMA-VEN. The mean overall survival (OS) of the BSC, HMA-mono, and HMA-VEN was 19.6 (SD 15.04), 25.9 (SD 28.87), and 51.7 (SD 49.09) weeks, respectively. In the HMA-VEN cohort there was no tumor lysis syndrome, 11 (55%) patients had an infection, and fourteen (70%) required hospitalization during the first two treatment cycles.</p><p><strong>Conclusion: </strong>HMA-VEN has been successfully integrated into standard care, which is primarily provided on an outpatient basis, and exhibits a safety and toxicity profile comparable to that of inpatient treatment. HMA-VEN is well tolerated subjectively in the subgroup of older patients and, in a historical comparison with the previous standard therapy, HMA-mono, or BSC, results in significantly longer overall survival without leading to an increase in complications or premature deaths.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"413-422"},"PeriodicalIF":1.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}